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Abstract
This narrative review of the literature provides a summary and discussion of 25 years of research into the complex links
between depression and diabetes. Systematic reviews have shown that depression occurs more frequently in people with
type 1 or type 2 diabetes compared with people without diabetes. Currently, it remains unclear whether depression is
also more common in people with impaired glucose metabolism or undiagnosed type 2 diabetes compared with people
without diabetes. More prospective epidemiological research into the course of depression and an exploration of
mechanisms in individuals with diabetes are needed. Depression in diabetes is associated with less optimal self-care
behaviours, suboptimal glycaemic control, impaired quality of life, incident micro- and macrovascular diseases, and
elevated mortality rates. Randomized controlled trails concluded that depression in diabetes can be treated with
antidepressant medication, cognitive–behavioural therapy (individual, group-based or web-based), mindfulness-based
cognitive therapy and stepped care. Although big strides forward have been made in the past 25 years, scientific evidence
about depression in diabetes remains incomplete. Future studies should investigate mechanisms that link both conditions
and test new diabetes-specific web- or app-based interventions for depression in diabetes. It is important to determine
whether treatment or prevention of depression prevents future diabetes complications and lowers mortality rates.
Diabet. Med. 37, 383–392 (2020)
Introduction
Depression is a serious and common psychiatric condition
that severely impairs the quality of life of those who suffer
from the disease. It is a heterogeneous disorder that is
diagnosed on the basis of clinical symptoms and the extent of
functional deterioration associated with these symptoms.
The syndrome comprises emotional symptoms (depressed
mood, irritability, anhedonia, feelings of guilt), cognitive
symptoms (depressed thoughts, suicidal ideation, feelings of
worthlessness, concentration problems), and behavioural or
somatic symptoms (hyperphagia or hypophagia and change
in weight, hypersomnia or insomnia, psychomotor retarda-
tion or activation, fatigue) [1]. A biological marker for
depression does not exists. According to Diagnostic and
Statistical Manual of Mental Disorders, fifth edition (DSM-
5), diagnosis of a major depressive episode can be made
when at least five of nine symptoms, including at least one
core symptom, are present for at least two weeks or longer.
Because different combinations of depression symptoms can
lead to a diagnosis, various clinical profiles of depression
exist. Depending on the symptom severity and symptom
count, a depressive episode can described as severe, moderate
or mild. The course of depression is described as first episode,
recurrent episode or chronic depression [1].
In the large World Health Surveys study [2] conducted in
245 404 participants from 60 countries, 9% (95% CI 7.3–
11.3) of respondents with diabetes also had depression, 11%
(95% CI 9.1–12.3) with arthritis were also depressed, as
were 15% (95% CI 12.9–17.2) with angina; persons with
asthma had the highest prevalence of depression at 18%
(95% CI 15.9–20.3). Thus, the prevalence of depression in
individuals with a chronic condition is significantly higher
than in those without (3.2%, P < 0.0001).
Depression is also perhaps the most commonly and longest
studied psychiatric problem in connection with diabetes. In
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the 17th century, the physician Thomas Willis, founding
Fellow of the Royal Society, noted that diabetes seemed to be
more common in people who had experienced sadness or
long sorrow [3]. Over the past 30 years, the number of
studies in this area has increased exponentially. A simple
literature search on 23 September 2019 entering the words
‘diabetes AND depression’ into PubMed yielded 1069 hits
for the period 1900–1994. The same search, but for the 25-
year period 1995–2019, resulted in a 10-fold higher result of
11 659 hits. In this article, we review the past 25 years of
research into the links between type 1 or type 2 diabetes and
depression.
What we knew in 1995
A systematic review, published in 1993, described the
prevalence of depression in adults with diabetes based on a
total of 20 studies [4]. Both clinical and community-based
samples were included and nine of the studies had a control
group. The reported prevalence of diagnosed depression in
people with diabetes ranged between 9% and 27% (average
14%) in studies with a control group, and between 11% and
20% in uncontrolled studies (average 15%) [4]. These
percentages were threefold higher than the rates of major
depression found in samples of adults without diabetes.
Investigations using depression symptom scales reported a
range of clinically significant depressive symptomatology in
people with diabetes of between 22% and 60% (average
32%) in controlled studies, and between 10% and 28%
(average 20%) in uncontrolled studies. In the mid-1990s,
little was known about the course of depression in diabetes.
In 1992, Lustman et al. [5] concluded that only one
systematic follow-up study was available. No studies had
examined depression as a risk factor for type 2 diabetes or
for diabetes complications, although based on three studies,
Alan Jacobson commented in December 1993 [6],
[. . .] it is reasonable to assume that this is a bidirectional
relationship with glycaemic control problems and depres-
sion affecting each other in reciprocal fashion. Thus,
depression may be a risk factor for the progression of the
consequences of poor metabolic control, i.e., the
microvascular and neuropathic complications of diabetes.
In those days, randomized controlled trials (RCTs) testing
pharmacological or psychological interventions for depres-
sion in diabetes were lacking. In 1992, Lustman et al. wrote
[5],
Pharmacotherapy of depression may improve both mood
and glucose regulation in diabetes, although controlled
studies of the efficacy of psychotherapy and pharma-
cotherapy for depression in diabetes are not yet available.
What we now know after 25 years of
research into diabetes and depression
Depression as a risk factor for type 2 diabetes
The first prospective investigation testing depression as a risk
factor for the development of type 2 diabetes was published
in 1996 [7]. In this study, which included 1715 participants
without diabetes at baseline, diagnosed major depression,
but not milder forms of depression or other forms of
psychiatric disorder, seemed to predict the onset of type 2
diabetes [although the estimated relative risk (RR) was not
significant: 2.23; 95% confidence interval (CI) 0.90–5.55]
[7]. Ten years later, the first meta-analysis was published
based on data from nine longitudinal studies, showing that
depressed adults have a 37% higher odds of developing type
2 diabetes [8]. A later meta-analysis based on 23 longitudinal
studies, involving 424 557 participants, with a mean follow-
up duration of 8.3 years, and 19 977 cases of incident
diabetes, confirmed these findings. The incidence of dia-
betes was higher in people with depression compared with
those without (0.72% vs. 0.47% yearly), with an unadjusted
and adjusted risk (95% CI) of 1.56 (1.37–1.77) and 1.38
(1.23–1.55), respectively [9].
The prevalence of depression in diabetes
Since 1995, several systematic reviews have summarized the
results of a considerable number of investigations with a
cross-sectional design that aimed to determine the prevalence
of depression in individuals with diabetes [10–15]. In most
What’s new?
• By 1995, a few epidemiological studies had concluded
that depression was more common in people with
diabetes than in those without. However, intervention
studies were lacking and longitudinal studies were
scarce.
• Over the past 25 years, research has confirmed the
bidirectional relationship between depression and type
2 diabetes.
• Depression in diabetes impairs quality of life and is
associated with less effective self-management, a higher
risk of diabetes complications and higher mortality
rates.
• Depression in diabetes can be treated effectively with
psychological and pharmacological therapy.
• Awareness of depression in people with diabetes should
be raised and adequate mental health care should be
available to treat depression.
• Future studies should elucidate the biological and
behavioural mechanisms that link depression and dia-
betes and test the long-term effects of treatment.
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papers, self-report measures of depression were utilized: few
used a diagnostic interview for the diagnosis of a mood
disorder. In the case–control studies, the risk of depression
was two times higher in comparison with individuals without
diabetes in studies that used self-report or a diagnostic
interview [10]. Research teams that aimed to assess the
prevalence of depression while using a self-report measure
generally found a two- to threefold higher prevalence of
depression (i.e. a high depression symptom severity) com-
pared with studies that used structured diagnostic interviews
(i.e. a diagnosed mood disorder) [10].
Buchberger et al. [15] conducted a systematic review of 14
papers and concluded that a high level of depressive
symptom severity was present in almost one-third of children
or adolescents with type 1 diabetes. Depression was more
than three times as common in adults with type 1 diabetes
(12% vs. 3%) and nearly twice as common in type 2 diabetes
(19% vs. 11%) in comparison with individuals without
diabetes [14]. A key limitation of this review was that it
mixed studies that utilized different methods to measure
depression [14]. A further systematic review that meta-
analysed 12 studies also concluded that depression was more
common in people with diagnosed type 2 diabetes in
comparison with those with a normal glucose metabolism
[13]. The paper also reported that the odds of depression
were not higher in individuals with screening diagnosed type
2 diabetes or impaired glucose metabolism (pre-diabetes)
compared with those with normal glucose metabolism [13].
A Chinese study also concluded that, compared with people
with normal glucose regulation (n = 120 458), people with
diabetes (n = 24 251) had higher odds of probable diagnosis
of depression (1.61, 95% CI 1.39–1.87) and sub-threshold
depression [odds ratio (OR) = 1.14, 95% CI 1.06–1.24],
whereas newly diagnosed diabetes (n = 24 826) or impaired
glucose regulation (n = 59 512) were not associated with
depression [16].
Two other cross-sectional studies have confirmed this
[17,18]. The LifeLines Study, another large study in this area,
analysed data from more than 90 000 individuals, including
from a diagnostic interview and an assessment of fasting
glucose. That study reported that both long-existing and
recently diagnosed diabetes (OR 1.8, 95% CI 1.3–2.6;
P = 0.001) were associated with an increased risk of
depression [19]. Individuals with impaired fasting glucose
(pre-diabetes) also had an increased risk of depression
compared with people without diabetes (OR 1.2–1.6,
dependent on how pre-diabetes was defined) [19].
Some symptoms of depression such as fatigue, disturbed
sleep or altered eating behaviours can also be symptoms of
suboptimal glycaemic control. Harding et al. [20] examined
the extent to which depression prevalence was dependent on
the amount of depression–diabetes symptom overlap (i.e.
itemswithin symptomdimensions) and sample characteristics.
In their review,Harding et al. included 147 studies that used24
validated depression questionnaires and found that diabetes–
depression symptom overlap did not affect prevalence rates.
Furthermore, studies that used a questionnaire with a higher
percentage of symptoms of anhedonia, cognition, negative
affect and disturbed sleep, and a lower proportion of somatic
symptoms reported a higher prevalence of depression [20].
Depressive symptom questionnaires have also been shown
to pick up diabetes distress, which may sometimes be the key
issue requiring attention. For example, Fisher et al. [21]
found a high percentage of false positives when they
compared the Patient Health Questionnaire Depression Scale
(PHQ-8) with a structured diagnostic interview, and an
unexpectedly low rate of major depression in persons with
type 1 diabetes. They also found that many people had high
levels of diabetes distress and the authors concluded that
emotional problems are often labelled as depression in adults
with type 1 diabetes although the symptoms may be better
regarded as diabetes–distress, resulting from having to
manage a chronic, demanding condition, or be due to other
life stressors. These persons with diabetes in particular,
perhaps need treatments that aim at reducing diabetes
distress and/or target other life stressors rather than focus
on depression [21].
Depression in diabetes: results from prospective studies
Only a few prospective investigations have studied the course
of depression in individuals with diabetes. A large study
undertaken by Kampling et al. [22] looked at the course of
depression over a period of 5 years in adolescence and early
adulthood (17–40 years) with recently diagnosed
(< 3 months) of type 1 diabetes. This longitudinal study
made use of diagnostic interviews during the baseline
assessment. Depression was measured by self-report only at
follow-up assessments as the diagnostic interviews were not
repeated. In 6% of persons with recently diagnosed type 1
diabetes, a comorbid major depression was also diagnosed,
whereas 8% appeared to have a comorbid anxiety disorder
[22]. This means that healthcare providers can expect that
one in ten people with recently diagnosed type 1 diabetes will
have a mood or anxiety disorder. In the 5-year follow-up
period, the majority (79%) of these young people with
diabetes did not experience depressive symptoms at any
assessment, 7% reported elevated depression scores that
showed improvement over time, while 14% had worse
depressive symptoms during follow-up [22].
A systematic review with meta-analysis of 11 longitudinal
studies showed that, compared with individuals without
diabetes, people with type 2 diabetes have a 24% increased
risk of developing depression [23]. A later systematic review
with meta-analysis of 16 longitudinal studies reported a
higher pooled OR for incident depression among respon-
dents with diabetes (1.34, 95% CI 1.14–1.57, v2 = 76.65,
I2 = 80.4%; P < 0.001), again confirming diabetes as a risk
factor for depression [24]. Nefs et al. [25] conducted a 3-year
longitudinal study of 2460 people with type 2 diabetes and
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examined the course (incidence, recurrence/persistence) of
depressive symptoms by self-report questionnaire in a
primary care setting. Among individuals with type 2
diabetes, 26% appeared to have at least one elevated
depression score during the 3-year study. Incident elevated
depression at one of the follow-up assessments was present in
14% of participants, while recurrent or persistent depression
was evident in 66% [22]. Depression in the past was the
strongest risk factor for a high depression score in the future
[25].
Depression in diabetes and long-term health outcomes
Depression substantially impairs quality of life in people with
diabetes [26]. Meta-analyses of longitudinal studies also
showed that individuals with diabetes and depression have
an elevated risk of developing not only microvascular, but
also macrovascular complications, a higher risk of cognitive
decline and also higher mortality rates [27,28]. A systematic
review with meta-analysis of 16 longitudinal diabetes studies
showed that, after adjustment for demographic variables and
micro- and macrovascular complications, baseline depression
was associated with an increased risk of all-cause mortality
[hazard ratio (HR) 1.46, 95% CI 1.29–1.66] and cardiovas-
cular mortality (HR 1.39, 95% CI 1.11–1.73] [28]. In the
meta-analysis, heterogeneity across studies was high for all-
cause mortality, but relatively low for cardiovascular mor-
tality. A comparison between type 1 and type 2 diabetes
could not be made because only one study focused on type 1
diabetes specifically [28].
Another systematic review of 22 longitudinal studies
investigated the relationships between depression and dia-
betes complications [27]. Sixteen papers investigated associ-
ations between depression and the incidence of diabetes
complications. A high baseline depression score was linked
to incident macrovascular (HR 1.38, 95% CI 1.30–1.47) and
microvascular disease (HR 1.33, 95% CI 1.25–1.41) com-
plications. Six longitudinal studies showed that persons with
diabetes complications had a higher risk of developing a
depressive disorder (HR 1.14, 95% CI 1.07–1.21) [27]. So,
not only is the association between diabetes and depression
bidirectional, but the same holds true for associations
between depression and diabetes complications. In both
cases, the risk of developing type 2 diabetes or diabetes
complications in people with depression is higher than the
risk of developing depression in people with diabetes or its
complications [27].
Suicidal ideation is an important and burdensome symp-
tom of depression. A recent systematic review of 17 studies
evaluated the risk of suicidality among people with diabetes.
Seven studies reported data on suicidal death that was
confirmed by either International Classification of Diseases
(ICD) codes or examination of the death certificate. Five
studies focused on suicide attempts or self-harm. Nine cross-
sectional studies examined suicidal ideation [29]. People with
diabetes were more often suicidal than people without
diabetes. The pooled OR values for suicidal ideation,
attempted suicide and completed suicide were 1.89 (95%
CI 1.36–2.63), 1.45 (95% CI 1.07–1.96) and 1.85 (95% CI
0.97–3.52), respectively [29].
Mechanisms linking depression and diabetes
The mechanisms that explain why depression is associated
with poor outcomes in diabetes are unclear and understudied
in individuals with type 1 diabetes. Current hypotheses
distinguish mechanisms at a behavioural level, such as the
burden of disease hypothesis and adverse lifestyle behaviour,
and at a biological level, involving the effects of hypergly-
caemia, hypothalamic–pituitary–adrenal (HPA) axis deregu-
lation, low-grade inflammation and microvascular
dysfunction [29–37]. From a behavioural perspective,
depression can impair several different self-care behaviours;
a systematic review of 47 studies concluded that depression
in people with diabetes was linked with less optimal self-care
behaviours, lower diet quality, less optimal medication use
and less frequent glucose monitoring, and lower appointment
keeping [30].
Based on the common ground hypothesis, several biolog-
ical mechanisms have been associated with poor diabetes
outcomes in people with diabetes and depression [31–37].
This hypothesis assumes that diabetes and depression have
common denominators, including genetic factors, overacti-
vation of the innate immune system or dysregulation of the
HPA axis. These common grounds could independently lead
to insulin resistance and an increased risk of type 2 diabetes,
cardiovascular disease and depression.
The strongest evidence for a shared genetic mechanism
comes from twin registries that can disentangle genetic from
shared environmental risk factors. Kan et al. [35] used
population-level data from the Swedish (n = 68 606)
and Danish (n = 95 403) twin registries and found that the
phenotypic correlation between type 2 diabetes and depres-
sion was modest in both samples, but also that genetic
background could explain the co-occurrence of diabetes and
depression. In a later study, based on data from the
CHARGE consortium (n = 51 258), and DIAGRAM con-
sortium (n = 34 840 people with diabetes and 114 981
controls), the genetic correlation between depressive symp-
toms and type 2 diabetes was estimated using single-
nucleotide polymorphism (SNP)-based heritability [36]. In
contrast to the twin studies, linkage disequilibrium score
regression analyses showed no significant genetic correlation
between depression and type 2 diabetes or glycaemic traits
[36]. Another study investigated the shared aetiology
between type 2 diabetes and major depressive disorder using
Mendelian randomization (MR) in a Scottish population-
based sample of 21 516 people [37]. Causality and genetic
overlap between type 2 diabetes and major depression were
assessed using polygenic risk scores that were obtained from
386 ª 2020 Diabetes UK
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the largest available genome-wide association study sum-
mary statistics to date [37]. No single type 2 diabetes risk
SNP was associated with major depression in the MR
analyses. In the same way, the results for the polygenic risk
scores analyses and also the linkage disequilibrium score
regression analyses showed no consistent evidence of genetic
overlap between major depression and type 2 diabetes [37].
However, the lack of genetic studies that explain the link
between depression and diabetes does not reject the common
ground hypothesis, as we know that the genetic predisposi-
tion of both diabetes and depression is modest. These
findings emphasize that the biological clues appear to be
the result of acquired behavioural and environmental factors,
more than genetic susceptibility.
In favour of this notion, Herder and Hermanns [33]
provide a narrative overview of epidemiological studies
that have investigated the associations between inflamma-
tory biomarkers and depressive symptoms or diagnosed
depression in people with diabetes. In people with type 1
diabetes, the evidence suggests that higher levels of
interleukin (IL)-1, IL-1 receptor antagonist (IL-1RA), IL-
6, high-sensitivity C-reactive protein (hsCRP), and soluble
intercellular adhesion molecule 1 may be related to depres-
sive symptoms or, for hsCRP, lower treatment response.
For people with type 2 diabetes, IL-1RA, hsCRP, chemo-
kine (C-C motif) ligand 2 and adiponectin or its isoforms
were associated with depressive symptoms in two or more
studies [33]. Positive associations were also reported
between IL-1b, IL-6 and IL-18 with depressive symptoms
or diagnosed depression in single studies. The authors
concluded that the number of studies in this area did not
allow for meta-analysis.
Furthermore, the vascular depression hypothesis may be
especially relevant in type 2 diabetes because diabetes is
strongly linked to microvascular and also cerebrovascular
damage. In addition, emerging evidence shows that markers
of cerebral small vessel disease (for example, white matter
hyperintensities and lacunar infarctions) are associated with
incident depression [34]; this fuels the hypothesis that
vascular damage in frontal and subcortical regions of the
brain, which are involved in mood regulation, may lead to
depression in later life [38]. Further evidence is needed to
substantiate the role of microvascular dysfunction in comor-
bid diabetes and depression.
Hoogendoorn et al. [39] recently discussed the results of
studies that investigated whether depression and type 2
diabetes can both result from dysregulation of homeostatic
brain–body pathways. In their study, the authors focus on
the role of the HPA axis and also the brain–gut–microbiome
(BGM) axis, and conclude that this dysregulation may be a
key intervention target for depression, type 2 diabetes and
their comorbidities. The authors also conclude that there is a
need for better studies that critically examine the potential
role of BGM axis. Future studies should thus carefully
investigate whether dysregulation of the BGM or HPA axes
is causally related to depressed mood, stress or the develop-
ment of type 2 diabetes [39].
Antidepressant use and diabetes
Barnard et al. [40] published a systematic review that
investigated whether antidepressant use was associated with
diabetes. The review is based on 21 observational studies,
comprising five case–control, four cross-sectional and 12
cohort studies. The authors concluded that there was some
evidence that antidepressant use is an independent risk factor
for type 2 diabetes. They also described how larger, more
recent studies that could include larger numbers of partici-
pants that received antidepressant medication suggest that
any risk is relatively small [40,41]. In a very large study of
138 659 women and 29 776 men, data from three large
studies were pooled to assess the risk of diabetes associated
with antidepressant medication use [41]. Use of antidepres-
sant medications was assessed biennially, and type of
antidepressant medication was recorded at later follow-up
measurements. Women were more often prescribed antide-
pressant medication than men. In the adjusted multivariable
analyses, baseline antidepressant use did not predict incident
diabetes, but use of any antidepressant medication was
associated with an elevated risk of diabetes in models that
were adjusted for differences in age (pooled HR 1.68, 95%
CI 1.27–2.23); these results suggest that recent use of
antidepressant medication might be more relevant to an
elevated diabetes risk [41]. In women, the average absolute
difference in risk between non-users and those taking
antidepressant medication was 2.87 per 1000 person-years.
After adjustment for diabetes risk factors, elevated choles-
terol, hypertension and BMI, the association became smaller
(HR 1.17, 95% CI 1.09–1.25) [36]. This may suggest that
use of antidepressant medication can contribute to diabetes
risk via an increase in body weight. New high-quality long-
term prospective studies on the effects of individual antide-
pressants are now warranted [40]. The lack of specificity in
relation to individual antidepressant drugs raises the possi-
bility that any association with diabetes could also result
from detection bias, as people with depression may receive
more frequent medical attention [42]. This hypothesis is
supported by results from the Whitehall II study, showing
that incident, physician-diagnosed diabetes was more fre-
quent among users of antidepressants compared with non-
users, whereas use of antidepressant medication was not
linked with undiagnosed diabetes [42].
Screening for depression in people with diabetes
Depression often remains undetected in diabetes and several
diabetes guidelines recommend screening for depression [43].
A systematic review of 21 studies identified that the Center
for Epidemiologic Studies Depression Scale (CES-D) and the
PHQ-9 are most frequently used in diabetes research [43].
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The CES-D appeared to have the highest sensitivity, whereas
the PHQ-9 had the highest specificity [43]. It is important to
emphasize that screening for depression in diabetes is only
effective if it is embedded in a comprehensive healthcare
system that offers subsequent diagnosis and appropriate
treatment options [44]. Without this being in place, screening
is unethical. Potential harms of screening also include the risk
that diabetes-distress is labelled as depression, the stigma
associated with depression, or possible discrimination by
insurance companies. The use of a depression screener could
also result in staff doing a routine procedure and ‘box tick’. It
can lead to the impression that psychological issues are
discussed, although other psychological problems such as
disturbed eating, sleeping problems, elevated diabetes dis-
tress or treatment dissatisfaction are not discussed. It is also
important that diabetes care professionals do not confuse a
high score on a questionnaire with a need for psychological
care. Asking the question: ‘Do you want professional support
for these problems’ might be as important as knowing
whether the person with diabetes is depressed. Collaboration
between healthcare professionals is a prerequisite for imple-
mentation of these strategies.
The treatment of depression in diabetes
A meta-analysis of 14 RCTs, published in 2010, tested
different interventions targeting depression in people with
diabetes [45]. The authors concluded that treatment was
effective in terms of reducing depression symptoms
(0.512; 95% CI  0.633 to  0.390) and that overall
effect of all interventions on clinical impact was moderate
(0.370; 95% CI  0.470 to  0.271). The largest effect
of psychotherapeutic interventions was seen when combined
with a diabetes self-management intervention (0.581;
95% CI  0.770 to  0.391) but was more moderate for
antidepressant medication (0.467; 95% CI  0.665
to  0.270). Collaborative care interventions for depression
in diabetes that provide stepped care in a primary care
setting, offering a choice of starting with psychotherapy or
pharmacotherapy, yielded an effect size of  0.292 (95%
CI  0.429 to  0.155). Except sertraline, antidepressant
medication and collaborative care had no effect on gly-
caemic control [45].
Another systematic review, published a few years later,
evaluated the effectiveness of cognitive–behavioural therapy
(CBT) on at least one of: HbA1c, depression, anxiety,
diabetes-related distress or quality of life in adults with type
1 or type 2 diabetes [46]. Based on the results of 12 RCTs,
the authors concluded that CBT is effective in reducing
depression and also short- and medium-term, but not long-
term, HbA1c. CBT improved short- and medium-term
anxiety and depression, and long-term depression [46].
Noordali et al. [47] conducted a systematic review that
evaluated the effectiveness of mindfulness-based cognitive
therapy (MBCT) in depressed or distressed people with
diabetes. They included 11 studies that satisfied the inclusion
criteria. Seven studies were RCTs, with the remainder having
either an observational or quasi-experimental design. MBCT
had mixed effects on physiological outcomes (HbA1c and
blood pressure), but appeared to reduce depression, anxiety
and distress symptoms across several studies [47].
A systematic review evaluated the cost-effectiveness of
treatment of depression [48]. Only four economic evalu-
ations were found but these studies reported that inter-
ventions reduced depression and were cost-effective
compared with care as usual [48]. These studies were all
conducted in the USA and evaluated collaborative care
programmes that included psychological therapies. Two
studies reported that costs per quality-adjust life year
(QALY) gained were US $267–4317; moreover, the other
two studies described net savings of $440–612 with the
intervention and net gains in depression free days or
QALYs [48].
Putting the evidence into practice
There is trial evidence showing that we can effectively treat
depression in diabetes. But how can we put the evidence into
practice? In a recent review article, Petrak et al. [44]
recommended a stepped care model, based on the current
scientific literature (Fig. 1). In that model [44], assessment of
depression severity and persistence of symptoms is a key task
that determines the treatment approach. It is also crucial that
the treatment response is monitored during all phases of this
stepped-care approach, and suicidal ideation is guarded
continuously at every step of care.
Step 1: subthreshold depressive symptoms that cause
impairment
If suicidal ideation and acute crisis are ruled out, interven-
tions for mild depression could probably be offered within
primary care. This could include giving self-help materials or
using an app- or web-based intervention that targets depres-
sion in people with diabetes. In case of a positive history of
severe, recurrent depression, selective serotonin-reuptake
inhibitors (SSRIs) or psychotherapy are to be considered.
Depressive symptoms should be monitored carefully over 2–
4 weeks; if no improvement is noted, treatment as described
in step 2 is indicated.
Step 2: moderate depression (or persistent mild depression
that does not respond to step 1)
Specific treatment for depression is advised in case of
persistent mild or moderate depression. Information should
be given about different psychological and pharmacological
treatment options that include CBT and SSRIs. For people
with recurrent depression, medication combined with psy-
chotherapy is recommended. In case of non-remission
observed after 2–4 weeks of treatment, the dose should be
increased or the type of drug can be changed.
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Step 3: severe depression or moderate depression not
responding to step 2
In case of severe depression, SSRIs are the first choice drug,
generally in combination with psychotherapy.
Step 4: very severe depression or severe depression not
responding to step 3
In case of very severe depression, treatment is often offered
on an inpatient basis, with a complex drug regimen.
Psychotherapy can be offered concomitantly with treatment
or after initial response to treatment.
When treating comorbid depression in diabetes, it is
important to take coexisting diabetes-distress into account.
The term diabetes-distress is used to describe a person’s
emotional responses to the burden of living with a largely
self-managed chronic disease and its debilitating complica-
tions, and comprises worries about hypoglycaemia, feeling
overwhelmed by diabetes, or feelings of guilt or anxiety when
one gets off track with diabetes management [49]. For people
with diabetes and depression who are also seriously dis-
tressed about their diabetes, depression treatment should
incorporate these concerns [49]. These individuals should
receive an integrated treatment, in which the diabetes
professionals (general practitioners, nurse practitioners and
endocrinologists) and mental health professionals (psychol-
ogists and psychiatrists) closely collaborate in a multidisci-
plinary context [49].
Despite our increased knowledge on the treatment of
depression in diabetes, depression appears to be highly
persistent and/or recurrent in type 2 diabetes. This suggests
that in people with type 2 diabetes depression remains
unnoticed and thus untreated, or that depression is resistant
to currently available treatments, or both [25]. Further
knowledge on the potentially common ground between the
co-existence of depression and diabetes can further improve
their clinical management. Psychosocial guidelines have
existed for many years in many countries, but are often not
applied in clinical practice. Therefore, further work is also
needed to support successful implementation of routine
assessments in clinical practice of psychological problems
including depression, with subsequent treatment if needed.
Future research
Meta-analyses have concluded that depression is linked to an
increased risk of developing type 2 diabetes. However, a
narrative review of longitudinal studies suggested that not
only depression, but also other psychological problems such
as general emotional stress, sleeping problems, anger and
Step 1: subthreshold depressive symptoms that cause impairment
Suicidal ideation and acute crisis should be  ruled out
Give self-help materials or use an app-based or web-based intervention that targets depression in people with 
diabetes. 
In case of a positive history of severe, recurrent depression, selective serotonin reuptake inhibitors (SSRIs) or 
psychotherapy are to be considered. 
Depressive symptoms should be monitored carefully over 2–4 weeks; if no improvement is noted, treatment as 
described in step 2 is indicated.
Step 2: moderate depression (or persistent mild depression that does not respond to step 1)
In case of persistent mild or moderate depression, specific treatment for depression is advised.
Information should be given about different psychological and pharmacological treatment options that include 
Cognitive Behavioural Therapy and SSRIs.  
For people with recurrent depression, medication combined with psychotherapy is recommended. In case of non-
remission observed after 2–4 weeks of treatment, the dose should be increased or the type of drug can be changed. 
Step 3: severe depression or moderate depression not responding to step 2
In case of severe depression, SSRIs are the first choice drug, generally in combination with psychotherapy. 
Step 4 very severe depression or severe depression not responding to step 3
In case of very severe depression treatment is often offered on an inpatient basis, with a complex drug regimen. 
Psychotherapy can be offered concomitantly with treatment or after initial response to treatment.
FIGURE 1 Stepped care model for depression in diabetes as described by Petrak et al. [44].
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hostility are associated with an increased risk of developing
type 2 diabetes [50]. For several other psychological factors,
such as childhood neglect or other adverse life events and
elevated work stress, findings were conflicting [50]. Using
cross-sectional data from surveys of 52 095 community-
dwelling adults in 19 countries, De Jonge et al. [51] found
that 16 DSM-IV disorders were associated with a diagnosis
of diabetes in bivariate models, but after comorbidity
adjustment only binge eating disorder (OR 2.6; 95% CI
1.7, 4.0), bulimia nervosa (OR 2.1; 95% CI 1.3, 3.4)
intermittent explosive disorder (OR 1.6; 95% CI 1.1, 2.1)
and depression (OR 1.3; 95% CI 1.1, 1.5) remained [51].
Future longitudinal studies should thus not only study
depression as a risk factor of diabetes, but also focus on
other psychiatric disorders [52]. Future studies should also
focus on the role and treatment of subtypes of depression,
such as atypical depression, melancholic depression, anxious
depression and the role of co-morbid diabetes-related distress
[49], while developing new web- and app-based interventions
for depression and diabetes-related distress in people with
diabetes [49,53]. It is clear that psychological and pharma-
cological treatments positively impact depression outcomes
in people with diabetes shortly after treatment and there are
short-term improvements in glycaemic control in pharmaco-
logical trials. However, there is still a lack of long-term
follow-up, which limits the evidence on the sustainability of
treatment effects [54] and its cost-effectiveness. It still
unclear whether intensive treatment of depression in dia-
betes, and perhaps comorbid diabetes-related distress can
improve future health outcomes by reducing the risk of
developing microvascular or macrovascular complications.
Conclusion
In the past 25 years, knowledge about the complex associ-
ations between depression and diabetes, and how to treat this
common and important clinical problem has increased
considerably. Although it is clear that depression in individ-
uals with diabetes is associated with less optimal diabetes
self-care, higher HbA1c, impaired quality of life, incident
micro- and macrovascular complications, and elevated mor-
tality rates, it is unclear whether intensive treatment of
depression in diabetes reduces the risk of developing diabetes
complications or prolongs life. Future studies should also
investigate the biological and behavioural mechanisms that
link both conditions and test innovative diabetes-specific e-
health interventions for depression in diabetes.
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